AU2022350407B2 - Interleukin-2 mutant and fusion protein thereof - Google Patents

Interleukin-2 mutant and fusion protein thereof

Info

Publication number
AU2022350407B2
AU2022350407B2 AU2022350407A AU2022350407A AU2022350407B2 AU 2022350407 B2 AU2022350407 B2 AU 2022350407B2 AU 2022350407 A AU2022350407 A AU 2022350407A AU 2022350407 A AU2022350407 A AU 2022350407A AU 2022350407 B2 AU2022350407 B2 AU 2022350407B2
Authority
AU
Australia
Prior art keywords
amino acid
antibody
protein
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022350407A
Other languages
English (en)
Other versions
AU2022350407A1 (en
Inventor
Fenggen FU
Jian Guan
Kaijie HE
Weiwei Wu
Shuaixiang ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fortvita Biologics (Singapore) Pte Ltd
Original Assignee
Fortvita Biologics (Singapore) Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fortvita Biologics (Singapore) Pte Ltd filed Critical Fortvita Biologics (Singapore) Pte Ltd
Publication of AU2022350407A1 publication Critical patent/AU2022350407A1/en
Application granted granted Critical
Publication of AU2022350407B2 publication Critical patent/AU2022350407B2/en
Priority to AU2025275202A priority Critical patent/AU2025275202A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2022350407A 2021-09-22 2022-09-21 Interleukin-2 mutant and fusion protein thereof Active AU2022350407B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025275202A AU2025275202A1 (en) 2021-09-22 2025-12-04 Interleukin-2 Mutant And Fusion Protein Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111110032 2021-09-22
CN202111110032.3 2021-09-22
PCT/CN2022/120265 WO2023045977A1 (zh) 2021-09-22 2022-09-21 白介素2突变体以及其融合蛋白

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025275202A Division AU2025275202A1 (en) 2021-09-22 2025-12-04 Interleukin-2 Mutant And Fusion Protein Thereof

Publications (2)

Publication Number Publication Date
AU2022350407A1 AU2022350407A1 (en) 2024-05-02
AU2022350407B2 true AU2022350407B2 (en) 2025-09-04

Family

ID=85720093

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022350407A Active AU2022350407B2 (en) 2021-09-22 2022-09-21 Interleukin-2 mutant and fusion protein thereof
AU2025275202A Pending AU2025275202A1 (en) 2021-09-22 2025-12-04 Interleukin-2 Mutant And Fusion Protein Thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025275202A Pending AU2025275202A1 (en) 2021-09-22 2025-12-04 Interleukin-2 Mutant And Fusion Protein Thereof

Country Status (14)

Country Link
US (2) US20240391973A1 (enExample)
EP (1) EP4406965A4 (enExample)
JP (2) JP7864826B2 (enExample)
KR (1) KR20240082364A (enExample)
CN (1) CN118119635A (enExample)
AU (2) AU2022350407B2 (enExample)
CA (1) CA3233075A1 (enExample)
CL (1) CL2024000834A1 (enExample)
CO (1) CO2024004910A2 (enExample)
IL (1) IL311643A (enExample)
MX (1) MX2024003535A (enExample)
PE (1) PE20241994A1 (enExample)
TW (1) TWI858393B (enExample)
WO (1) WO2023045977A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112105634B (zh) 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
KR20220155316A (ko) * 2020-03-19 2022-11-22 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 인터루킨-2 돌연변이 및 이의 용도
WO2025007037A1 (en) * 2023-06-28 2025-01-02 Dragonfly Therapeutics, Inc. Variant il-2 proteins
WO2025031434A1 (zh) * 2023-08-08 2025-02-13 北京志道生物科技有限公司 经修饰的细胞因子与cd40激动剂的联用组合物及其抗肿瘤用途
AU2024411090A1 (en) 2023-12-28 2026-07-16 Fortvita Biologics (Singapore) Pte. Ltd. Pd-1/il-2r bispecific antibody fusion protein, and use and usage method thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
CN118373896B (zh) * 2024-04-19 2025-07-29 上海科棋药业科技有限公司 抗pd-1抗体与il-2突变体的双功能融合蛋白
WO2025252212A1 (zh) * 2024-06-07 2025-12-11 福佑泰生物制药公司 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用
WO2026012466A1 (en) * 2024-07-12 2026-01-15 Vibrant Pharma Limited Interleukin-2 muteins and uses thereof
CN118546233B (zh) * 2024-07-30 2024-10-18 成都微芯新域生物技术有限公司 白介素-21突变体及其应用
WO2026083295A1 (en) * 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
CN121293311B (zh) * 2025-08-01 2026-07-24 合肥天港免疫药物有限公司 Il-2变体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020057645A1 (zh) * 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
JP7765181B2 (ja) * 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
CN111868079B (zh) * 2017-12-27 2025-06-17 协和麒麟株式会社 Il-2变体
CA3143034A1 (en) * 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
KR20220155316A (ko) * 2020-03-19 2022-11-22 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 인터루킨-2 돌연변이 및 이의 용도
WO2021185362A1 (zh) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 白介素2突变体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020057645A1 (zh) * 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途

Also Published As

Publication number Publication date
TW202320862A (zh) 2023-06-01
US20260053898A1 (en) 2026-02-26
EP4406965A1 (en) 2024-07-31
AU2025275202A1 (en) 2026-02-19
CO2024004910A2 (es) 2024-07-08
CA3233075A1 (en) 2023-03-30
WO2023045977A1 (zh) 2023-03-30
US20240391973A1 (en) 2024-11-28
CL2024000834A1 (es) 2024-09-06
EP4406965A4 (en) 2025-12-17
TWI858393B (zh) 2024-10-11
KR20240082364A (ko) 2024-06-10
JP2024534545A (ja) 2024-09-20
JP2026097838A (ja) 2026-06-16
AU2022350407A1 (en) 2024-05-02
CN118119635A (zh) 2024-05-31
JP7864826B2 (ja) 2026-05-25
MX2024003535A (es) 2024-05-07
PE20241994A1 (es) 2024-09-27
IL311643A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
US20260053898A1 (en) Interleukin-2 mutant and fusion protein thereof
AU2021408214B2 (en) Interleukin-21 mutant and use thereof
CN113301919B (zh) 激活免疫细胞的双特异性抗体
US20250051413A1 (en) Chimeric molecules comprising il-12 agonist polypeptide
CN106103488B (zh) 靶向TGFβ抑制
BR112021006783A2 (pt) proteína de fusão fc heterodimérica de il-15/r¿ direcionada, composição de ácido nucleico, composição de vetor de expressão, célula hospedeira, e, métodos de produção da proteína de fusão fc heterodimérica de il-15/r¿ direcionada e de tratamento de um câncer.
CN110305210A (zh) 新型抗体分子、其制备方法及其用途
JP2019519223A (ja) 免疫調節タンパク質及び腫瘍抗原に結合する二重特異性結合タンパク質
KR20220155316A (ko) 인터루킨-2 돌연변이 및 이의 용도
KR20230171465A (ko) 항cldn4-항cd137 이중특이성 항체
US20250243275A1 (en) Multi-domain binding molecules
US20250333507A1 (en) Fusion protein of anti-tigit antibody and il2 or variant thereof, and application thereof
EP4559932A1 (en) Multispecific antibody and use thereof
KR20230108288A (ko) 항tspan8-항cd3 이중 특이성 항체 및 항tspan8 항체
EP4650368A1 (en) Tetravalent agonists of erythropoietin receptor
EP4524248A1 (en) Anti-taa/anti-cd3 multispecific antibody
WO2026016967A1 (zh) 一种融合蛋白及其用途
CN118725136A (zh) 抗pd-1/抗tigit双特异性抗体与il-2的融合蛋白及应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)